Immunome, Inc.

NASDAQ:IMNM

Biotechnology

Healthcare
$16.78 -2.26%

-$0.42 today

Market cap
$1.98B
Beta
2.07
P/E (TTM)
-9.1
EPS (TTM)
-$1.99
52W Low $7.96High $27.65

Volume 1.41M

Average 1.23M

IMNM Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Immunome, Inc.NASDAQ: IMNM

Operating Income · Q3 FY2026 · quarter ended Sep 2026

Operating income remains negative

Q3 FY2026 operating income was -$90.36M, compared with -$60.14M a year earlier. Trailing-twelve-month operating income was -$300.69M.

Context

  • Operating income amounted to 3084.8% of revenue in FY2025, down 297.6 pp from a year earlier.
  • Operating income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate from 7 analysts of -$221.64M (-3.5%) for the fiscal year ending Dec 2026, a slowdown from the +30.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$90.36M-15.6% QoQ
Last fiscal yearDec 2025
-$214.11M+30.0% YoY
LTMSep 2026
-$300.69M-28.4% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-50.3%-12.9%+37.4 pp
1 year+30.0%-3.5%-33.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(214.11M) USD
Year-over-year change
+30.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How IMNM compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -28.4% is the 6th highest of 11, against a peer median of -21.1%.
IMNM Competitors
Operating Income for IMNM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMCRImmunocore Holdings plcLTM Mar 2026-$29.36M USD+38.3%—7.6%
IMMXImmix Biopharma, Inc.LTM Mar 2026-$36.08M USD-65.8%——
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026-$39.45M USD-46.4%——
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$47.93M USD-53.5%——
MGNXMacroGenics, Inc.LTM Mar 2026-$63.66M USD+36.0%—40.5%
STROSutro Biopharma, Inc.LTM Mar 2026-$115.08M USD+54.0%—115.5%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026-$156.87M USD-11.7%——
IMTXImmatics N.V.LTM Mar 2026-€212.71M EUR-251.5%—570.3%
BCYCBicycle Therapeutics plcLTM Mar 2026-$242.4M USD+2.4%—381.8%
IMNMImmunome, Inc.LTM Sep 2026-$300.69M USD-28.4%——
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$334.5M USD-30.5%—298657.1%
Peer median (excluding IMNM) —-21.1%—248.6%

Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0014.02M9.04M6.94M
Cost of Revenue00002.96M
Gross Profit0014.02M9.04M3.99M
Gross Margin——100.0%100.0%57.4%
Research & Development14.11M23.27M23.09M129.54M174.33M
Selling, General & Admin11.09M13.63M19.66M32.96M43.77M
Operating Expenses25.2M36.9M123.55M314.84M218.1M
Depreciation & Amortization755K631K728K2.1M2.96M
EBITDA(23.95M)(36.26M)(28M)(151.35M)(209.44M)
EBITDA Margin——-199.7%-1674.1%-3017.4%
Operating Income(25.2M)(36.9M)(109.53M)(305.8M)(214.11M)
Operating Margin——-781.4%-3382.4%-3084.8%
Interest Income10K5K2.72M12.84M11.72M
Interest Expense10K5K000
Other Income / Expenses493K5K2.72M12.84M1.72M
Income Before Tax(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Pre-Tax Margin——-761.9%-3240.4%-3060.0%
Income Tax Expense00000
Net Income(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Net Margin——-761.9%-3240.4%-3060.0%
EPS (Basic)(2.14)(3.09)(5.38)(5.00)(2.43)
EPS (Diluted)(2.14)(3.09)(5.38)(5.00)(2.43)
Weighted Avg Shares11.54M12.13M19.84M58.64M87.35M
Weighted Avg Shares (Diluted)11.54M12.13M19.84M58.64M87.35M

Immunome, Inc.

NASDAQ:IMNM

Intrinsic Alpha fair value

Locked

Current Price

$16.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.